➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Mallinckrodt
Boehringer Ingelheim
Dow
Colorcon

Last Updated: May 16, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR AMISULPRIDE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Amisulpride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00126009 SOLMANIA - Comparison of Valproate-Amisulpride and Valproate-Haloperidol in Bipolar I Patients Completed Sanofi Phase 2 2004-05-01 The primary objective is: - To compare the efficacy of the association valproate-amisulpride (400 to 800 mg/day) to the association valproate-haloperidol (5 to 15 mg/day) in bipolar I patients suffering from a manic episode according to DSM IV TR (American Psychiatric Association [APA] 2000) and treated for a 3-month period. The secondary objectives are: - To evaluate the clinical and biological safety of the association valproate-amisulpride to the association valproate-haloperidol; - To assess the patient status 3 weeks and 3 months after inclusion; and - To assess patient satisfaction at 3 months.
NCT00204061 Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis Completed Department of Psychiatry University of Bonn Phase 4 2001-01-01 The study will provide an empirical basis for a pharmacological treatment option. An open-label, randomized, multi-centre parallel group design is used. An intensified clinical management (CM), which allows needs-based psychological crisis intervention, is compared to a combination of such a CM and the atypical neuroleptic amisulpride. The central hypothesis is that the combination of a clinical management with an atypical neuroleptic is the superior treatment.
NCT00204061 Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis Completed German Federal Ministry of Education and Research Phase 4 2001-01-01 The study will provide an empirical basis for a pharmacological treatment option. An open-label, randomized, multi-centre parallel group design is used. An intensified clinical management (CM), which allows needs-based psychological crisis intervention, is compared to a combination of such a CM and the atypical neuroleptic amisulpride. The central hypothesis is that the combination of a clinical management with an atypical neuroleptic is the superior treatment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Amisulpride

Condition Name

Condition Name for Amisulpride
Intervention Trials
Schizophrenia 34
Schizophreniform Disorder 4
Schizoaffective Disorder 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Amisulpride
Intervention Trials
Schizophrenia 35
Psychotic Disorders 11
Disease 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Amisulpride

Trials by Country

Trials by Country for Amisulpride
Location Trials
Germany 22
United States 17
Spain 11
United Kingdom 8
Canada 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Amisulpride
Location Trials
North Carolina 3
Massachusetts 3
Ohio 3
Florida 3
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Amisulpride

Clinical Trial Phase

Clinical Trial Phase for Amisulpride
Clinical Trial Phase Trials
Phase 4 22
Phase 3 9
Phase 2 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Amisulpride
Clinical Trial Phase Trials
Completed 31
Not yet recruiting 11
Recruiting 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Amisulpride

Sponsor Name

Sponsor Name for Amisulpride
Sponsor Trials
Sanofi 8
Acacia Pharma Ltd 6
Technische Universität München 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Amisulpride
Sponsor Trials
Other 82
Industry 22
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Baxter
McKinsey
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.